Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
KR

NASDAQ · KRRO

Korro Bio, Inc.

Healthcare · Biotechnology

$9.97

Down-$0.21 (-2.11%)

Updated Oct 6, 2026, 10:31 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
74.09M
P/E ratio
-0.81
Dividend yield
0.00%
52-week range
$9.12 – $15.56
Volume
112.22K
Avg. volume
526.07K

Price performance · KRRO

KRRO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

KRRO closed at $9.97 after 20 trading sessions, down 26.20% for the selected period.

Last close
$9.97
Period change
-26.20%
Period low
$9.51
Period high
$14.07
Daily close
View OHLC price history
KRRO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$9.70$10.10$9.41$9.97112.22K
Oct 2, 2026$9.90$9.90$9.4775$9.64153.13K
Oct 1, 2026$9.93$10.2699$9.465$9.7188.78K
Sep 30, 2026$9.89$10.01$9.50$9.91108.14K
Sep 29, 2026$9.56$9.80$9.30$9.5692.88K
Sep 28, 2026$9.49$9.655$9.24$9.51132.44K
Sep 25, 2026$9.64$9.64$9.40$9.57114.42K
Sep 24, 2026$9.71$9.75$9.41$9.57197.46K
Sep 23, 2026$10.31$10.31$9.55$9.83224.72K
Sep 22, 2026$10.08$10.5842$10.01$10.34213.48K
Sep 21, 2026$10.12$10.77$9.86$9.98290.52K
Sep 18, 2026$11.71$11.945$9.505$10.02763.4K
Sep 17, 2026$14.18$14.355$11.76$11.80400.44K
Sep 16, 2026$14.15$14.8637$13.44$13.83304.66K
Sep 15, 2026$13.87$14.20$12.98$14.07162.6K
Sep 14, 2026$13.59$15.15$13.555$13.88264.8K
Sep 11, 2026$13.28$14.06$13.1738$13.81197.97K
Sep 10, 2026$12.80$13.16$12.38$13.06145.8K
Sep 9, 2026$13.44$13.76$12.87$12.93131.5K
Sep 8, 2026$12.03$13.62$11.89$13.51119.12K

Latest KRRO news

The latest Smart Investors Daily articles mentioning KRRO.

Stock researchCompany · Overview

KRRO research

Overview

Company profile and research snapshot.

Company profile

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$91.25
Implied upside
—
Analysts
16
KRRO recent ratings
DateFirmRatingTarget
Aug 20, 2026HC Wainwright & Co.Buy—
May 19, 2026HC Wainwright & Co.Buy—
May 18, 2026CitigroupBuy—
Mar 13, 2026Cantor FitzgeraldOverweight—
Mar 13, 2026Raymond JamesOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees. Korro granted the new employees nonstatutory stock options to purchase 5,000 shares of Korro’s common stock, in the aggregate, at

Yahoo · Aug 27, 2026

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences: Citi 2026 Biopharma Back to School SummitFormat: Fireside chat moderated by Yigal Nochomovitz,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By